Almirall launches new anti-inflammatory drug Ilumetri (tildrakizumab) in Germany

recently, Spain'sPharmaceutical(http://company(http://Almirall announced the launch of a new anti-inflammatory drug in Germany, Tildrakizumab, for the treatment of adult patients with moderate to severe plaque psoriasis suitable for systemic therapyIlumetri's medication regimen is 100mg of subcutaneous injections in the 0th and 4th weeks, followed by 100mg of subcutaneous injections every 3 monthsIlumetri's listing also marks Theof bio
pharmaceutical http://, which plans to push Itumetri into other European markets in the coming monthsabout Ilumetri
Ilumetri is a human-induced monoclonal antibody that selectively and highaffinity binds to the p19 subunit of IL-23, inhibiting the results of its and IL-23 receptors, thereby inhibiting the release of pro-inflammatory cytokines and chemokinesIlumetri will provide patients with a simple treatment plan, after the completion of the first treatment of the 0th and 4th weeks, the follow-up maintenance treatment period every 3 months of subcutaneous injection, that is, only 4 times a year, will provide patients with greater convenience, achieve better disease control, improve treatment satisfactiontime to study thein the European Union, Ilumetri was approved in September this year, the approval of the drug is based on data from two key Phase III clinical studies (reSURFACE-1, reSURFACE-2)Both studies were randomized, placebo-controlled, multicenter clinical studies with more than 1,800 cases in the group and were conducted in more than 200 clinical
trial (http:// institutions worldwide The main endpoints of the study were that at the 12th week of treatment, the Ilumetri treatment group achieved a 75% skin removal rate (psoriasis area sensitivity index or PASI75) and a physician's overall assessment scale (PGA) score of 0 (clear) or 1 (minimum) for patients compared to the placebo group data show that in the 12th week of treatment, an average of 63% of patients in the Ilumetri treatment group achieved PASI75 remission, 78% of patients reached PASI75 remission in week 28, and 59% of patients reached PASI90 and 30% of patients reached PASI100 More than 92% of patients who achieved remission during the 28-week treatment period were able to maintain PASI75 remission after one year in the U.S market, tildrakizumab was approved in March 2018 and listed under the brand name Ilumya (tildrakizumab-asmn) for use in adult patients with moderate to severe plaque psoriasis suitable for system therapy or phototherapy